Drug Trial Radar · NCT07673068
Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of TVAX-028 in the Treatment of Chronic Hepatitis B
Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
May 31, 2026
Primary completion
May 31, 2027
Study completion May 31, 2027
Sponsor
- Lead sponsor
- Grand Theravac Life Sciences (Nanjing) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, non-randomized, Phase 1 clinical study with single-dose and multiple-dose dose-escalation cohorts. The study is designed to evaluate the safety, tolerability, and pharmacokinetic characteristics of TVAX-028 in patients with chronic hepatitis B virus infection
Conditions
- HBV Infection
Interventions
TVAX-028Drug
TVAX-028 will be administered with adjuvant at low, medium, or high dose levels in the investigational dose groups.
AdjuvantOther
Adjuvant will be administered alone in the adjuvant group
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse eventsTime frame: Through the end of the safety follow-up period, an average of 60 weeks
- Number of participants with dose-limiting toxicitiesTime frame: Through the end of the safety follow-up period, an average of 60 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.